From: Cancer immunotherapies targeting the PD-1 signaling pathway
Target | Agent | IgG class | Company | Approved |
---|---|---|---|---|
PD-1 | nivolumab (Opdivo®, BMS-936558, MDX1106) | Human IgG4 | Bristol-Meyers Squibb/Ono |
MelanomaU, E, J
Lung cancerU, E, J Kidney cancerU, J Hodgkin’s lymphoma U, E, J Head and neck cancer U Urothelial cancer U |
pembrolizumab (Keytruda®MK-3475, lambrolizumab) | Humanized IgG4 | Merck |
MelanomaU, E, J
Lung cancerU, E, J Head and neck cancerU | |
pidilizumab (CT-011) | Humanized IgG1k | Cure Tech | ||
AMP-224 | PD-L2 IgG2a fusion protein | Amplimmune/GlaxoSmith Klein | ||
AMP-514 (MEDI0680) | PD-L2 fusion protein | Amplimmune/GlaxoSmith Klein | ||
PDR001 | Humanized IgG4 | Novartis Pharmaceuticals | ||
PD-L1 | BMS-936559 (MDX1105) | Human IgG4 | Bristol-Meyers Squibb | |
atezolizumab (Tecentriq®, MPDL3280A) | Humanized IgG1k | Roche/Genentech |
Urothelial cancerU
Lung cancerU | |
durvalumab (MEDI4736) | Human IgG1k | MedImmune/AstraZeneca | ||
avelumab (MSB0010718C) | Human IgG1 | Merck Serono/Pfizer |